



TOS 2021 Review Course for the ABOM Exam Continuing Medical Education Information for Learners

Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this live activity for a maximum of 17.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Learning Objectives

1. Use evidence-based diagnostic/assessment tools to determine which treatment is most appropriate for specific patient types.
2. Develop appropriate behavioral, pharmacological and bariatric approaches for the treatment of patients with obesity.
3. Apply the options that are currently available to develop strategies to treat patients with obesity including dietary strategies, physical activity interventions, medications and surgical options.
4. Implement evidence-based approaches for the treatment of obesity and to be able to explain it in terms easily understood by the patient.
5. Incorporate evidence-based factors that predispose patients to weight gain—including genetic factors, relevant neuropeptides, alterations in energy expenditure and environmental factors—into appropriate patient-treatment strategies.
6. To acquire strategies that foster translation of predispositions into appropriate clinical treatment for patients with obesity.

Commercial Support

No commercial support was received for this activity.

Faculty and Planning Committee Disclosure Information

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all financial relationships with ineligible companies¹. This information is disclosed to CME activity participants. The Obesity Society has procedures to mitigate all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed. TOS requires additional disclosures beyond the ACCME definition of an ineligible company. These include food, weight loss, and supplement industry disclosures. In the list below, the nature of the relationship and company are followed by the industry of that company.

Speaker Disclosures:

Name	2021 Speaker Disclosures
Bays, Harold (MD, FTOS, FOMA, FACC, FNLA, FASPC)	Contracted Research relationship with Boehringer Ingelheim (Pharmaceuticals); Eli Lilly (Pharmaceuticals); Epitee (Pharmaceuticals); Novo Nordisk (Pharmaceuticals); Pfizer (Pharmaceuticals). Speakers Bureau relationship with Novo Nordisk (Pharmaceuticals). Consulting Fee relationship with Gelesis (Pharmaceuticals).
Courcoulas, Anita (MD, MPH, FACS)	No Relevant Financial Relationships
Donahoo, William (MD)	No Relevant Financial Relationships
Gilden, Adam (MD, MSCE, FACP)	No Relevant Financial Relationships
Jakicic, John (PhD, FTOS, FACSM)	Consulting Fee relationship with WW International, Inc. (Weight Management) and Wondr Health (Weight Management).
Jensen, Michael (MD)	investigator initiated research grant relationship with Novo Nordisk (Pharmaceuticals).

¹ An ineligible company as defined by the ACCME is one that is not eligible for ACCME accreditation, in other words those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 1) Advertising, marketing, or communication firms whose clients are ineligible companies, 2) Bio-medical startups that have begun a governmental regulatory approval process, 3) Compounding pharmacies that manufacture proprietary compound, 4) Device manufacturers or distributors, 5) Diagnostic labs that sell proprietary products, 6) Growers, distributors, manufacturers or sellers of medical foods and dietary supplements, 7) Manufacturers of health-related wearable products, 8) Pharmaceutical companies or distributors, 9) Pharmacy benefit managers, 10) Reagent manufacturers or sellers. Reference: <https://accme.org/faq/what-accmes-definition-ineligible-company>

Name	2021 Speaker Disclosures
Peterson, Ninoska (PhD)	No Relevant Financial Relationships
Shah, Meera (MD)	No Relevant Financial Relationships
Skelton, Joseph (MD, MS)	No Relevant Financial Relationships

Planner Disclosures: TOS Annual Meeting Program Committee disclosures:

Name	Role	2021 Planner Disclosures
Butryn, Meghan (PhD)	Committee Member	No Relevant Financial Relationships
Collazo-Clavell, Maria (MD)	Committee Member	No Relevant Financial Relationships
Davidson, Lance (PhD)	Committee Member	No Relevant Financial Relationships
Gilden, Adam (MD, MSCE, FACP)	Co-Director	No Relevant Financial Relationships
Purnell, Jonathan (MD, FTOS)	Co-Director	Consulting Fee relationship with Novo Nordisk (Pharmaceuticals)

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee. One committee member did step down upon developing a potential conflict.

Name	Role	2021 TOS Annual Meeting Review Disclosure
Tchang, Beverly (MD)	CME Oversight Committee Member	Accepted a consulting contract with Novo Nordisk on Feb 1, 2021 and stepped down from the TOS CME oversight committee. Prior to that date, had no relevant financial relationships.

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

This document was last updated November 4, 2021.